I’m always surprised when the same people who are so strict about diet and exercise still drink every single day — something we now now causes cancer:
— bettina pearl (@bettinaapearl) April 3, 2022
Myocarditis is extremely rare — except in people who have had covid:
Myocarditis has been found in at least 5 Big Ten athletes. Anyone downplaying this in an effort to justify playing has no idea of the logistical challenges and risks. Putting things on hold while we sort out these risks is the right call.@TheAMSSMhttps://t.co/PqsF61hNaU— Chad Carlson (@ccarlsonin) August 10, 2020
(Editor’s note: Far be it from me to think they leaked this to bump the stock, but it does seem promising.)
A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.
Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.
The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.
“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.
Below is a link where one can look up when a state will reach the point of no return for hospitals being overwhelmed with Covid-19 patients.